Press Releases

Shanghai, China, Dec. 13, 2022 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it was awarded a Bronze Medal for its sustainability management and performance by EcoVadis, the world’s most trusted provider of business sustainability ratings.

EcoVadis’ evidence-based assessments are built on international sustainability standards – including the Global Reporting Initiative, the United Nations Global Compact, and ISO 26000 – covering over 200 industries and 175 countries. This rating is a critical reference for WuXi Biologics’ strategic partners – notably all global pharmaceutical companies – in evaluating sustainability performance and the benefits of collaboration. The Bronze Medal recognition reflects WuXi Biologics’ commitment to reducing its environmental impact and promoting sustainable business practices, both within the company and across its community.

Dr. Chris Chen, WuXi Biologics’ CEO and Chairperson of the company’s Environmental, Social, and Governance (ESG) Committee, commented, “We are very pleased that our ESG efforts have been recognized by EcoVadis. WuXi Biologics remained – and remains – committed to the ongoing implementation of our ESG strategy, which plays a critical role in our long-term sustainable development as a trusted partner. We will continue to enable global partners to discover, develop, and manufacture biologics for the benefit of patients worldwide.”

WuXi Biologics views ESG responsibilities as an integral component of its business strategy and works to achieve sustainable performance in a wide range of areas, including procurement. The company established a cross-function Sustainable Procurement Task Force and has made continual progress in building a strong, reliable and responsible supply chain by enhancing suppliers’ sustainable performance in the fields of environmental protection, climate change response, labor rights, business ethics and more. By leveraging the “Multi-Sourcing and Safety Stock” approach, WuXi Biologics mitigates potential risks from such supply chain disruptions as the COVID-19 pandemic, and ensures delivery of high-quality products and services for its global clients.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts 
 
Media

PR@wuxibiologics.com

ESG

ESG@wuxibiologics.com